Impact of Clinical Characteristics and Management on the Prognosis of Unselected Heart Failure Patients
- 294 Downloads
Heart failure (HF) is a major public health issue. This study conducted a real-life analysis of the impact of clinical characteristics and medical management of HF on its prognosis.
Analysis was based on the EGB (“Echantillon Généraliste des Bénéficiaires”) database. A cohort comprising 1825 adult patients with a first admission for HF between 2009 and 2011 was created and followed until June 2013 (median 22.3 [7.7–34.5] months) for survival analysis.
Mean age was 77.3 ± 13.2 years (53 % ≥80 years). The overall incidence of HF admission was 117 [112–122] per 100,000 population with a marked increase in patients >80 years (1297 [1217–1348]). At discharge, only 8 % of patients received recommended combination of angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARB), beta-blockers (BB) and mineralocorticoid receptor antagonists (MRA). Only prescription levels of BB and vitamin K antagonists, at discharge, increased during the study period. In-hospital mortality was 9 % and survival was 71.6 %[69.5–73.6] and 52.0 %[49.4–54.6] at 12 and 36 months, respectively. In multivariate analysis, female gender [HR:0.78 (0.67–0.91), p = 0.001], ACEi/ARB + BB + MRA [0.41 (0.28–0.60), p < 0.001] and ACEi/ARB + BB [0.47 (0.39–0.57) p < 0.001] treatments were associated with improved survival, conversely to age 70–79 [1.90 (1.20–3.00), p = 0.003] and ≥80 [3.50 (2.30–5.40), p < 0.001], cardiogenic shock [3.00 (2.10–4.40), p < 0.001], acute pulmonary edema [1.70 (1.10–2.50), p = 0.01], denutrition [1.80 (1.45–2.24), p < 0.001], dilated cardiomyopathy [1.20 (1.00–1.40), p = 0.02] and in-hospital acute renal failure [1.36 (1.05–1.78), p = 0.002].
These real-life HF data provide insight into prognostic factors and “real-world” pharmacological management in this unselected HF population, confirming the benefit of ACEi/ARB + BB ± MRAs on patient survival.
KeywordsHeart failure Epidemiology Management Therapeutics
We thank Mr. Pierre Pothier for the editing of this manuscript.
Conflict of Interest
- 3.McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC. Eur Heart J. 2012;33:1787–847.CrossRefPubMedGoogle Scholar
- 6.Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, et al. The EuroHeart failure survey programme– a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24:442–63.CrossRefPubMedGoogle Scholar
- 21.Fonarow GC, Heywood JT, Heidenreich PA, Lopatin M, Yancy CW, ADHERE. Scientific advisory committee and investigators. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from acute decompensated heart failure national registry (ADHERE). Am Heart J. 2007;153:1021–8.CrossRefPubMedGoogle Scholar
- 23.Yeung DF, Boom NK, Guo H, Lee DS, Schultz SE, Tu JV. Trends in the incidence and outcomes of heart failure in Ontario, Canada: 1997 to 2007. CMAJ. 2012;184:E765–73.Google Scholar
- 26.Zannad F, Briancon S, Juilliere Y, Mertes PM, Villemot JP, Alla F, et al. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL study. Epidémiologie de l’insuffisance cardiaque avancee en lorraine. J Am Coll Cardiol. 1999;33:734–42.CrossRefPubMedGoogle Scholar
- 30.Oluleye OW, Rector TS, Win S, McMurray JJ, Zile M, Komajda M, et al. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circ Heart Fail. 2014.Google Scholar
- 34.Shekelle PG, Rich MW, Morton SC, Atkinson CSW, Tu W, Maglione M, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol. 2003;41:1529–38.CrossRefPubMedGoogle Scholar
- 36.Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P, Poole-Wilson PA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European society of cardiology. Developed in collaboration with the heart failure association of the ESC (HFA) and endorsed by the European society of intensive care medicine (ESICM). Eur Heart J. 2008;29:2388–442.CrossRefPubMedGoogle Scholar